Skip to main content
. 2017 Mar 31;36(10):1434–1446. doi: 10.15252/embj.201695669

Figure 5. USP49 regulates response of pancreatic cancer cells to chemotherapy through the AKT pathway.

Figure 5

  • A
    Cell lysates from pancreatic cancer cell lines were blotted with USP49 and FKBP51 antibodies. Lysates from normal pancreatic (HPDE6‐E6E7c7) epithelial cells were used as a control.
  • B
    BXPC3 cells were stably infected with retrovirus encoding control (Ctrl) or FLAG‐USP49. Cells were lysed and cell lysates were blotted with the indicated antibodies.
  • C–E
    Cells from (B) were treated with (C) gemcitabine, (D) etoposide, or (E) cisplatin. Cell survival was determined.
  • F
    SU86 cells stably expressing USP49 shRNAs were lysed and cell lysates were blotted with indicated antibodies.
  • G–I
    Cells from (F) were treated with (G) gemcitabine, (H) etoposide, or (I) cisplatin and cell survival was determined.
  • J
    BXPC3 cells stably infected with retrovirus encoding control (Ctrl) or FLAG‐USP49 were treated with MK‐2206 (1 μM) for 4 h, cells were lysed and cell lysates were then blotted with the indicated antibodies.
  • K
    Cells from (J) were treated as indicated, and cell survival was determined.
  • L
    Cells from Fig 3G were treated as indicated, and cell survival was determined.
Data information: The data presented are mean ± SD (n = 6).